Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 05 09 2018
revised: 10 10 2018
accepted: 02 11 2018
pubmed: 13 11 2018
medline: 7 9 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Ureteral stricture is a rare but severe side effect of radiation therapy for locally advanced cervical cancer. This report describes the incidence and risk factors for ureteral stricture in a large patient cohort treated with 3-dimensional image guided adaptive brachytherapy and radiochemotherapy within the EMBRACE studies. A total of 1860 patients were included. Treatment consisted of external beam radiation therapy (45-50 Gy in 25-30 fractions), concomitant cisplatin, and image guided adaptive brachytherapy. Grade 3 to 4 ureteral strictures were assessed with Common Terminology Criteria for Adverse Events v. 3.0. Risk factors for grade 3 to 4 ureteral stricture were analyzed. These factors included age, hydronephrosis on imaging at time of diagnosis, TNM stage, high-risk clinical target volume, laparoscopic staging, chemotherapy, radiation therapy doses to targets and organs at risk, applicator type, intracavitary versus intracavitary/interstitial technique, and dose rate. At a median follow-up of 34 months (range, 2-163), 31 patients received diagnoses of grade 3 to 4 ureteral stricture. Actuarial 3- and 5-year risk for ureteral stricture grade 3 to 4 was 1.7% and 2.1%, respectively, for all patients. Advanced tumor stage T3-4 with hydronephrosis at diagnosis was the only independent risk factors for ureteral stricture (P = .01). Patients with TNM stage T1 (n = 359) had a low risk of 0.4% and 1.0% at 3 and 5 years, and those with T2 (n = 1085) had a low risk of 1.0% and 1.0% at 3 and 5 years, respectively. Patients (n = 274) with T3-T4 without hydronephrosis at diagnosis had a 3- and 5-year risk of 2.2% and 4.8%, respectively, compared with 11.5% and 11.5%, respectively, in those with baseline hydronephrosis (n = 142). Severe to life-threatening ureteral stricture occurs rarely in patients with locally advanced cervical cancer with T1-2 tumors. The risk for ureteral stricture is significantly increased in patients with T3-T4 tumors with hydronephrosis at diagnosis.

Identifiants

pubmed: 30419309
pii: S0360-3016(18)33953-1
doi: 10.1016/j.ijrobp.2018.11.006
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-894

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Lars Fokdal (L)

Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: Larfok@rm.dk.

Kari Tanderup (K)

Department of Oncology, Aarhus University Hospital, Denmark.

Richard Pötter (R)

Department of Radiation Oncology, Medical University of Vienna, Austria.

Alina Sturdza (A)

Department of Radiation Oncology, Medical University of Vienna, Austria.

Kathrin Kirchheiner (K)

Department of Radiation Oncology, Medical University of Vienna, Austria.

Cyrus Chargari (C)

Department of Radiotherapy, Gustave-Roussy, France.

Ina Maria Jürgenliemk-Schulz (IM)

Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands.

Barbara Segedin (B)

Department of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia.

Li-Tee Tan (LT)

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom.

Peter Hoskin (P)

Mount Vernon Cancer Centre, Northwood, United Kingdom.

Umesh Mahantshetty (U)

Department of Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

Kjersti Bruheim (K)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Bhavana Rai (B)

Department of Radiation Oncology, Regional Cancer Centre, Chandigarh, India.

Christian Kirisits (C)

Department of Radiation Oncology, Medical University of Vienna, Austria.

Jacob Christian Lindegaard (JC)

Department of Oncology, Aarhus University Hospital, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH